NovaBay's Pipeline
We are developing two primary compounds. NVC-422 is our lead compound in a new class of antimicrobial compounds that we call the Aganocide ® compounds, which we intend to use in the development of products to treat various bacterial infections. NovaBay has two issued U.S. patents on the use of NVC-101 (also referred to as NeutroPhase ® ) for promoting wound healing, tissue repair and tissue regeneration, and for disinfection or decontamination of open wounds and burns. NeutroPhase has received two 510(k) clearances from the FDA as a Class I device.
Internal Products - Aganocide ® Compounds
| Indication | Market | Clinical Status |
| Urinary Catheter Blockage and Encrustation (UCBE) | ~300,000 permanently catheterized patients | Phase 2 |
| Ophthalmic | 5M annual cases of conjunctivitis | Phase 2 |
| Onychomycosis (fungal nail infection) | 30M patients | Pre-Clinical |
Internal Products - NeutroPhase ®
| Indication | Market | Clinical Status |
| Wound healing | 6M annual cases of chronic non-healing wounds | Two FDA 510(k) clearances |
Partnered Products
| Product | Indication | Market Size | Clinical Status | Licensee |
| NVC-422 | Impetigo | ~13M Rx written in 2009 | Phase 2 | Galderma |
* Galderma Partnership: NBY Retains some rights in Asia
(0)
(0)
